The past few years have been challenging for many life science companies, both in the private setting but also those on public markets, and the IPO window for new listings has been essentially closed. The industry is dependent on the availability of capital as well as the risk appetite, both impacted by macroeconomic factors. Deal-making and M&A (merges and acquisitions) with pharma are the lifeblood of the industry.

In this episode, Ted Fjällman speaks to Tim Opler. Having taken part in more than 150 transactions with a total value of $100 billion, Tim shares his expertise and elaborates on different ways of financing innovation, a booming obesity field, and how patents are currently central to gaining a competitive advantage, but not the only measure.

Prostate cancer remains one of the most prevalent and costly cancers globally, posing challenges for both early detection and effective management. The healthcare burden continues to rise as more patients require advanced therapies and long-term care.

In this episode, Dr. Ted Fjällman and Professor Henrik Grönberg, delve into the rising healthcare burden of prostate cancer. They discuss breakthroughs in research, emerging treatment strategies, and how these developments can address the challenges in detection, management, and long-term care to improve patient lives.

Professor Grönberg is a shareholder in A3P Biomedical